Skip to main content

Advanced therapies · United Kingdom

Gene therapy in the UK — real treatment, not just research.

Casgevy, Zolgensma, Luxturna, Roctavian, Hemgenix, Libmeldy and CAR-T are all NICE-approved and NHS-commissioned in 2026. Access is limited to a handful of specialist centres — we help you find the right pathway.

See approved therapies
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why patients choose us

  • 01

    Real treatment, not a trial

    Dozens of gene therapies are now NICE-approved and NHS-commissioned in the UK — Casgevy, Zolgensma, Luxturna, Roctavian, CAR-T and more. We help you find the pathway.

  • 02

    Rare-disease MDT access

    Gene therapy is only delivered in a handful of specialist centres. We map the right MDT, the right consultant and the right commissioning route for your condition.

  • 03

    Independent, and free

    We are not tied to any manufacturer, centre or clinic. The recommendation is impartial and the concierge is free to you.

UK-approved gene therapies

What is NICE-approved and NHS-commissioned in 2026.

List prices are what manufacturers charge — NHS access is via confidential commercial agreements and specialist commissioning. Patients do not pay out of pocket.

In short

Casgevy — the world’s first CRISPR therapy — is NHS-commissioned in the UK: NICE TA1011/1012, 2024.

Therapy Indicative cost
Onasemnogene abeparvovec (Zolgensma) — SMA type 1 £1.79M list (NHS)
Voretigene neparvovec (Luxturna) — RPE65 IRD £613k per eye (NHS)
Casgevy — sickle cell / β-thalassaemia (CRISPR) £1.65M list (NHS)
Roctavian — haemophilia A (AAV5) £1.85M list (NHS)
Hemgenix — haemophilia B (AAV5) £2.6M list (NHS)
CAR-T (Kymriah, Yescarta, Tecartus, Carvykti) £280k–£450k (NHS)
Libmeldy — metachromatic leukodystrophy £2.87M list (NHS)
Concierge navigation and MDT introduction Free

List prices are for context — actual NHS spend is governed by confidential managed-access agreements negotiated by NHS England and the Cancer Drugs Fund. Access is decided by your specialist MDT against strict eligibility criteria.

The problem

The right diagnosis, the right product, the right centre.

Gene therapy is real — but access is narrow, information is fragmented, and pathways are opaque. We fix all three before you spend months waiting on the wrong route.

  • Diagnosis unclear?

    We route you to Genomics England or an accredited panel before anything else — no confirmed genotype, no eligible therapy.

  • Product ambiguous?

    Multiple products for one condition (SMA has Zolgensma and Spinraza). We compare NICE criteria and the evidence honestly.

  • Centre unknown?

    Only a handful of NHS centres deliver each therapy. We map the closest accredited MDT and coordinate the referral.

The journey

From enquiry to lifetime follow-up — what happens, in order.

A rare-disease MDT leads clinically. We handle navigation, commissioning paperwork and the long-tail of registry follow-up.

  1. 01

    Before

    You tell us the diagnosis

    A short, confidential form. The condition, the genetic confirmation (Genomics England or private panel), age and prior treatments.

  2. 02

    Before

    We map the eligible therapy

    Within one to two working days: which licensed product applies, whether NICE has issued a TA, and which UK specialist centre delivers it.

  3. 03

    Before

    Referral and commissioning

    We coordinate the NHS England Highly Specialised Services referral, Cancer Drugs Fund route or individual funding request — with your consultant leading.

  4. 04

    Delivery

    Workup, apheresis or vector delivery

    Ex-vivo therapies need cell collection and conditioning chemotherapy. In-vivo AAV therapies are given as a single infusion, subretinal injection or intrathecal dose.

  5. 05

    Delivery

    Inpatient recovery

    A short hospital stay for monitoring — cytokine release, hepatic function, immune response, engraftment. Length varies by platform.

  6. 06

    After

    First-year intensive follow-up

    Frequent bloods, imaging and disease-specific biomarkers. Immune monitoring and antibody surveillance where relevant.

  7. 07

    After

    Long-term registry follow-up

    Five to fifteen years — sometimes lifetime — under a mandated registry. Durability, delayed toxicity and secondary malignancy surveillance.

Typical end-to-end: 3–6 months from referral to infusion. Registry follow-up: 5–15 years or lifetime.

When it helps

When gene therapy is the right step.

The indications with a licensed UK product in 2026, plus the one situation where the first step is genetic testing, not therapy.

  • Spinal muscular atrophy (SMA)

    Type 1 in infants under 24 months — onasemnogene abeparvovec (Zolgensma). Nusinersen (Spinraza) for all types.

  • Sickle cell disease

    Recurrent vaso-occlusive crises with failed hydroxycarbamide — Casgevy CRISPR gene editing, or Lyfgenia (assessment ongoing).

  • Transfusion-dependent β-thalassaemia

    Regular transfusions and no matched sibling donor — Casgevy ex-vivo gene editing via NHS England.

  • Haemophilia A or B

    Severe factor VIII or IX deficiency — Roctavian (AAV5) for A, Hemgenix (AAV5) for B. Single infusion, years of factor-free bleeding.

  • Inherited retinal dystrophy (RPE65)

    Biallelic RPE65 mutations with viable retinal cells — voretigene neparvovec (Luxturna) subretinal AAV.

  • Metachromatic leukodystrophy (MLD)

    Pre-symptomatic late-infantile or early-juvenile disease — Libmeldy autologous lentiviral gene therapy.

  • Haematological cancers (CAR-T)

    Relapsed/refractory B-cell lymphomas, ALL, multiple myeloma — Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti.

  • Red flag: no genetic confirmation

    Gene therapy needs a confirmed molecular diagnosis. If genetics are unclear, the first step is Genomics England panel testing — not a therapy referral.

Modalities

Gene therapy is not one thing — it is eight.

Different modalities suit different diseases. The delivery route, the vector serotype and whether the treatment is in-vivo or ex-vivo all shape eligibility and follow-up.

  • Ex-vivo autologous cell therapy

    Your own cells collected by apheresis, modified in a lab, and reinfused after conditioning chemotherapy. CAR-T, Casgevy, Libmeldy, Strimvelis.

  • In-vivo AAV vector (systemic)

    A single intravenous infusion of an adeno-associated virus carrying the therapeutic gene. Zolgensma, Roctavian, Hemgenix — often one dose for life.

  • In-vivo AAV vector (local)

    Delivered directly to the target tissue — subretinal for Luxturna, intrathecal for CNS-directed therapies, intramuscular for some pipeline products.

  • CRISPR/Cas9 gene editing

    Precise cutting and repair of a target gene. Currently ex-vivo (Casgevy for haemoglobinopathies) with in-vivo CRISPR emerging in trials.

  • Antisense oligonucleotide (ASO)

    Repeated intrathecal or subcutaneous dosing to modulate RNA. Spinraza for SMA, Exondys for Duchenne, eplontersen for hATTR.

  • siRNA / RNAi therapies

    Small interfering RNA silences a disease-causing gene. Patisiran and vutrisiran for hATTR amyloidosis, givosiran for AIP, lumasiran for PH1.

  • Lentiviral gene addition

    Integrating vector used ex-vivo — Libmeldy for MLD, historical Strimvelis for ADA-SCID. Long-term integration requires lifetime monitoring.

  • Pipeline and clinical trials

    Active UK trials in LHON, choroideraemia, USH1B, XLRP, achromatopsia and in-vivo CRISPR. We can point you to the relevant NIHR trial site.

Our vetted UK network

NHS commissioned centres, we know how to reach them.

A handful of centres in London, Manchester, Sheffield, Newcastle, Birmingham and Bristol deliver gene therapy in the UK. We map the closest accredited MDT for your product and coordinate the referral privately.

Selection criteria

How we choose every centre in our network.

A UK cell and gene therapy laboratory
NHS commissioned ATMP centres
  • NHS England commissioned gene therapy centres — not general private clinics

  • Consultant leadership by geneticist, haematologist, ophthalmologist or oncologist with product-specific accreditation

  • Genomics England confirmation or accredited private panel before referral

  • Long-term registry follow-up (5–15 years, sometimes lifetime) organised at the outset

Safety and monitoring

What to expect — honestly, and by platform.

Every gene therapy carries platform-specific risks and needs long-term surveillance. Nothing here is a substitute for the consent discussion at the treating centre — but you should walk in knowing the shape of it.

  • CAR-T: CRS and ICANS

    Cytokine release syndrome and neurotoxicity (ICANS) are the two big early risks. Managed with tocilizumab, steroids, ICU support in specialist centres.

  • AAV: hepatotoxicity

    High-dose IV AAV (Zolgensma, Roctavian, Hemgenix) can trigger transient liver enzyme rises. Steroid cover and weekly LFTs for months are standard.

  • AAV: neutralising antibodies

    Once dosed, most patients develop antibodies to the vector — redosing is usually not possible. Pre-treatment antibody screening decides eligibility.

  • Ex-vivo: myeloablative conditioning

    Casgevy, Libmeldy and CAR-T (for ALL) need chemotherapy before infusion. Risks include infection, cytopenias, infertility and, rarely, GvHD-like effects.

  • Secondary malignancy — FDA warning 2024

    The FDA issued a class warning for CAR-T secondary T-cell malignancies. Rare but real; part of the lifelong monitoring.

  • CRISPR: off-target editing

    Theoretical off-target edits are extensively screened pre-approval. Real-world durability data for Casgevy is early but strong so far.

  • Variable and incomplete response

    Not every patient responds fully. Zolgensma works best under six months; Luxturna needs viable RPE cells; CAR-T remission rates vary by indication.

  • Cost and access

    Products list at £500k–£3M. NHS access is via NICE TA plus specialist commissioning — not self-pay in the UK for most indications.

  • Red flags

    Fever, breathlessness, confusion, unexplained bleeding or new jaundice after gene therapy — contact the treating centre immediately, not your GP.

Reading your treatment summary

Your gene therapy summary in four parts. Read the last one first.

Whichever product was used, the summary the centre sends you keeps to the same shape.

A UK consultant reviewing a patient’s gene therapy treatment summary

A quiet reminder

Molecular and vector language is dense — we translate it for you.

If you would like us to talk you through the summary before your review, just ask.

  1. 01 Header

    Diagnosis, genotype and product used

    The condition, the confirmed genotype (and where tested — Genomics England or private lab), and the licensed product administered.

  2. 02 Technique

    Dose, vector and delivery route

    The vector serotype (AAV5, AAV9, lentivirus, etc), dose in vg/kg or cells/kg, delivery route, and any pre-conditioning chemotherapy.

  3. 03 Findings

    Response, biomarkers and antibodies

    Disease-specific biomarkers (factor VIII levels, HbF percentage, motor milestones, visual acuity), vector shedding, and immune response.

  4. 04 Impression

    Follow-up schedule and registry

    Read this first: the mandated long-term registry (5–15 years or lifetime), red-flag symptoms, and who to contact for what.

Recognised by major UK insurers

BupaAXA HealthVitalityAvivaWPACignaHealixBupaAXA HealthVitalityAvivaWPACignaHealixBupaAXA HealthVitalityAvivaWPACignaHealix

UK gene therapy is delivered under NHS England Highly Specialised Services, the Cancer Drugs Fund and NICE-approved managed access. Private insurance rarely funds ATMP products directly — we clarify the route before referral.

Frequently asked

Everything we get asked about gene therapy in the UK.

Straight answers on approved products, NHS access, CRISPR, in-vivo vs ex-vivo, risks and long-term follow-up.

  • Is gene therapy actually available on the NHS in 2026?

    Yes — dozens of NICE-approved gene therapies are commissioned by NHS England, including Casgevy (CRISPR for sickle cell and β-thalassaemia), Zolgensma (SMA), Luxturna (RPE65 retinal dystrophy), Roctavian (haemophilia A), Hemgenix (haemophilia B) and multiple CAR-T products. Access is via specialist centres and Highly Specialised Services commissioning.

  • Can I pay for gene therapy privately in the UK?

    For most licensed products, no. List prices run £500k–£3M and delivery is restricted to a small number of accredited NHS centres. A handful of CAR-T products can be arranged privately for select oncology cases. We tell you honestly which route applies to your condition.

  • What is Casgevy and how does CRISPR gene editing work?

    Casgevy (exagamglogene autotemcel) is the world’s first approved CRISPR gene-editing therapy. Your bone marrow stem cells are collected, edited to reactivate fetal haemoglobin, and reinfused after conditioning chemotherapy. NICE approved it in 2024 for sickle cell disease (TA1011) and transfusion-dependent β-thalassaemia (TA1012).

  • How is Zolgensma different from Spinraza?

    Zolgensma is a one-time AAV9 gene therapy that delivers a working SMN1 gene — for SMA type 1 infants under 24 months (NICE TA755). Spinraza (nusinersen) is an antisense oligonucleotide given intrathecally every four months, approved for all SMA types (NICE TA588). They are different modalities with different pathways.

  • What is the difference between in-vivo and ex-vivo gene therapy?

    In-vivo therapies are delivered directly into your body — usually as a single IV infusion, subretinal injection or intrathecal dose using an AAV vector. Ex-vivo therapies collect your cells (or donor cells), modify them in a lab, and reinfuse them after conditioning chemotherapy. CAR-T, Casgevy, Libmeldy and Strimvelis are ex-vivo; Zolgensma, Luxturna, Roctavian and Hemgenix are in-vivo.

  • What are the main risks of gene therapy?

    They are platform-specific. CAR-T carries cytokine release syndrome, neurotoxicity and a class warning for secondary T-cell malignancies. AAV therapies can cause transient hepatotoxicity and generate neutralising antibodies that prevent redosing. Ex-vivo therapies involve conditioning chemotherapy with infection, cytopenia and infertility risks. Long-term durability data is still accumulating for most products.

  • How long does follow-up last after gene therapy?

    Between five and fifteen years for most products, and lifetime for lentiviral and CRISPR platforms — under a mandated registry. Follow-up covers durability of response, delayed toxicity, immune surveillance and, for integrating vectors, monitoring for secondary malignancy.

  • What is Genomics England and why does it matter?

    Genomics England runs the NHS Genomic Medicine Service, offering whole-genome and panel testing for rare-disease and cancer patients. A confirmed molecular diagnosis is a prerequisite for almost every gene therapy referral — so the first step, if genetics are unclear, is testing not therapy.

  • How do I get referred for gene therapy in the UK?

    Through a rare-disease MDT or specialist consultant — paediatric neurology for SMA, haematology for sickle cell/thalassaemia/haemophilia, ophthalmology for RPE65, or oncology for CAR-T. NHS England commissioning is via Highly Specialised Services, the Cancer Drugs Fund or an individual funding request. We map the right route for your case.

WhatsApp Call us
Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

Confidential. We respond within one working day.